口腔鳞状细胞癌肿瘤标志物联合检测
Combination assay for tumor markers in oral squamous cell carcinoma.
作者信息
Kurokawa H, Yamashita Y, Tokudome S, Kajiyama M
机构信息
Second Department of Oral and Maxillofacial Surgery, Kyushu Dental College, Kitakyushu, Japan.
出版信息
J Oral Maxillofac Surg. 1997 Sep;55(9):964-6. doi: 10.1016/s0278-2391(97)90071-9.
PURPOSE
This study evaluated use of a combination assay of tumor markers in the diagnosis of oral squamous cell carcinoma.
PATIENTS AND METHODS
Serum levels of four tumor markers (carcinoembryonic antigen [CEA], squamous cell carcinoma antigen [SCCA], immunosuppressive acidic protein [IAP], and cytokeratin 19 fragment [Cyfra]) were simultaneously measured in 42 patients with oral squamous cell carcinoma (O-SCC) and in 12 patients with oral benign diseases.
RESULTS
The positive rates were 31.0% for CEA, 38.1% for SCCA, 52.4% for IAP, and 38.1% for Cyfra in patients with O-SCC. These rates were significantly different (P < .01) from those of control patients with oral benign diseases. The sensitivity (81.0%) and accuracy (77.8%) of the combination assay uses higher than that obtained with individual markers.
CONCLUSION
A combination assay with CEA, SCCA, IAP, and Cyfra may be useful for the screening of patients with suspected oral squamous cell carcinoma.
目的
本研究评估了肿瘤标志物联合检测在口腔鳞状细胞癌诊断中的应用。
患者与方法
对42例口腔鳞状细胞癌（O-SCC）患者和12例口腔良性疾病患者同时检测了四种肿瘤标志物（癌胚抗原[CEA]、鳞状细胞癌抗原[SCCA]、免疫抑制酸性蛋白[IAP]和细胞角蛋白19片段[Cyfra]）的血清水平。
结果
O-SCC患者中，CEA的阳性率为31.0%，SCCA为38.1%，IAP为52.4%，Cyfra为38.1%。这些比率与口腔良性疾病对照患者的比率有显著差异（P < .01）。联合检测的敏感性（81.0%）和准确性（77.8%）高于单个标志物检测。
结论
CEA、SCCA、IAP和Cyfra联合检测可能有助于筛查疑似口腔鳞状细胞癌患者。
Zotero 插件